Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
|Articles|May 26, 2015
Adare Pharmaceuticals: Improving solubility. Creating new possibilities for patients.
The bioavailability of a drug is strongly dependent on its solubility in the gastrointestinal tract. At Adare, we have proprietary technologies available to help improve the solubility of oral drugs. BioriseTM Bioavailability Enhancement Technology
Advertisement
The bioavailability of a drug is strongly dependent on its solubility in the gastrointestinal tract. At Adare, we have proprietary technologies available to help improve the solubility of oral drugs.
Biorise™ Bioavailability Enhancement Technology
Biorise™ Bioavailability Enhancement Technology is used to enhance bioavailability of drugs that are poorly soluble at physiological pHs.
This technology creates new physical entities (NPEs) with better solubility profiles. These NPEs are produced by breaking down the crystalline drug into nanocrystals and/or amorphous (non-crystalline) drug particles that are stabilized in a carrier system to maintain the drug in its activated form for the duration of its shelf life.
This approach transforms the original crystalline form of the drug into an amorphous and/or nanocrystalline, thermodynamically activated solid form-characterized by higher solubility-thereby enhancing the rate and extent of absorption in the gastrointestinal tract.
With a broad range of proprietary technologies, Adare can help you overcome formulation challenges. To learn more about Biorise™ Bioavailability Enhancement Technology and our other proprietary technologies, contact
©2015 Adare Pharmaceuticals, Inc.
Advertisement
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Advertisement
Advertisement